Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
701
-
702
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…<p>Cell lysates were obtained from THP-1 monocytes exposed to reagents as indicated: Lane 1, vehicle; Lane 2, PARP inhibitor olaparib (5 mM, 24 hr); Lane 3, oxLDL (100 mg/mL, 24 hr) or Lane 4, combination of oxLDL and olaparib. …”
-
703
-
704
-
705
BA decreases mitochondrial membrane potential and superoxide production after one day of cell culture.
Published 2022“…<p>(A) Representative contour plots of MT-Green/TMRE-stained B cells after incubation with 0.5 mM BA for 1 day. …”
-
706
-
707
-
708
-
709
-
710
-
711
-
712
-
713
-
714
-
715
-
716
MCP-1-deficiency decreased CD11c-expressing cells via impairing the production of ROS and decreased activation of PLCγ2, Akt, and ERK upon M-CSF stimulation in BMM.
Published 2013“…<p>BMMs from WT (open bar) and MCP-1-KO mice (oblique-lined bar) were incubated in the presence of M-CSF (30 ng/ml) with U73122 (10 µM), Akt inhibitor IV (0.3 µM), PD098059 (5 µM), DPI (50 nM), NAC (3 mM), or H<sub>2</sub>O<sub>2</sub> (300 µM) for 4 d (A). *, <i>P</i><0.05; ***, <i>P</i><0.001 compared with vehicle-treated WT cells. …”
-
717
-
718
-
719
-
720